TGA Compliance and Enforcement Priorities (2026–2027)
The Therapeutic Goods Administration (TGA) has outlined its key compliance principles and enforcement priorities for 2026–2027, with an increased focus on digital environments and emerging risks.
Core Compliance Principles
Proactive Monitoring of Advertising
The TGA will undertake active surveillance of advertising activities, with particular emphasis on digital platforms.
Crackdown on Unapproved and Substandard Products
Enforcement efforts will target the supply of unapproved, counterfeit, and substandard therapeutic goods across e-commerce and social media channels.
Improving Access to Compliance Information
Through guidance and educational initiatives, the TGA aims to enhance awareness and accessibility of compliance requirements for consumers, industry stakeholders, and other relevant parties.
Addressing Misleading and False Information Online
The TGA will strengthen its response to misleading or deceptive content, including material გავრცელ across social media platforms and influencer marketing.
Enhancing Compliance Tools and Tackling AI-Related Risks
Regulatory capabilities will be upgraded to address risks associated with AI-generated misinformation and deceptive endorsements. At the same time, the TGA will increase the visibility of enforcement actions and maintain a strong focus on non-compliance in digital channels.
Priority Areas for 2026
According to the document, from 1 January 2026, the TGA’s compliance and enforcement activities will focus on 12 categories of therapeutic goods, including vaping goods.
The TGA has also indicated that the next review of these priority areas is scheduled for March 2026.
Ongoing Enforcement Approach
In addition to the identified priority areas, the TGA will continue to investigate and act on other compliance matters as they arise. Regulatory action may be taken against any identified non-compliance, regardless of whether it falls within the current priority categories.